MiNK Therapeutics

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company’s platform is designed to support scalable manufacturing of engineered and native iNKT cell programs, with a pipeline that includes therapies for solid tumors and inflammatory conditions. MiNK Therapeutics works at the intersection of cell therapy and immunology, using iNKT cells that are intended to combine tumor-targeting activity with immune-regulating properties. Its current work centers on advancing product candidates through clinical development and building a manufacturing approach suited to reproducible, off-the-shelf delivery. Headquartered in New York, MiNK Therapeutics plays a specialized role in the biotechnology market by developing precision immunotherapies for serious diseases with limited treatment options.